Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Newron Pharmaceuticals SpA logo — The Specialist in CNS Drug Development

Newron Pharmaceuticals SpA

The Specialist in CNS Drug Development

Founded 1999 Italy Italy 23 employees Post-IPO Equity Total: $129.36M Biopharma, Biotechnology +1

General Information

Company Name Newron Pharmaceuticals SpA
Founded Year 1999
Location Italy Italy
Employees 23
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Newron Pharmaceuticals SpA. To contact Newron Pharmaceuticals SpA, visit newron.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Newron Pharmaceuticals SpA compare?

A PDF of Newron Pharmaceuticals SpA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Newron Pharmaceuticals SpA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Newron Pharmaceuticals SpA

Newron Pharmaceuticals is a biopharmaceutical company headquartered in Italy, with a subsidiary in the USA. The company, founded in 1999, specializes in developing novel therapies for diseases of the central nervous system (CNS) and pain. With a balanced and robust pipeline of drug candidates at different clinical stages, Newron has a proven track record of drug development and commercialization. One of its notable successes is the marketing authorization and commercialization of Xadago® (safinamide) for the treatment of Parkinson’s disease in various regions including the European Union, Switzerland, the US, and other markets. Additionally, the company has a promising pipeline of treatments including Evenamide as an add-on therapy for schizophrenia and ralfinamide for specific rare pain indications. In 2017, Newron raised a Fr.27.00M Post-IPO Equity investment. Despite not specifying the investors, this investment demonstrates continued interest and support for the company's innovative approaches in the biopharma, biotechnology, and health care industries. As a publicly listed company on the SIX Swiss Exchange, Düsseldorf Stock Exchange, and XETRA, Newron Pharmaceuticals continues to showcase a strong commitment to delivering innovative treatments to improve the quality of life for patients with CNS disorders.

Business keywords: biopharmaceutical, CNS drug development, Parkinson's disease treatment, neurological disorders, rare diseases, pharmaceutical commercialization, clinical development, schizophrenia treatment, drug candidates, innovative therapies, SIX Swiss Exchange, European pharmaceutical companies, US pharmaceutical market, Neurological drug research, Italian biopharmaceutical companies

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Fr.27.00M -
26 Sep 2017
Post IPO Equity Fr.26.10M -
07 Oct 2016
Post IPO Equity $5.40M -
20 Nov 2015
Post IPO Equity $22.76M -
30 Apr 2015
Post IPO Equity Fr.4.70M -
23 Aug 2012
Post IPO Equity Fr.3.50M -
22 Dec 2010
Post IPO Equity Fr.7.90M -
20 Nov 2009
Series B €7.00M 5
Atlas Venture 3i Group Apax Partners
Atlas Venture, 3i Group +3
05 Oct 2005
Venture Round €25.00M 3
Atlas Venture 3i Group Apax Partners
Atlas Venture, 3i Group +1
01 Apr 2002
Venture Round Undisclosed 1
3i Group
3i Group
01 Jan 1999

Newron Pharmaceuticals SpA Alternatives & Competitors

View All Alternatives
Newron Pharmaceuticals SpA vs
Chase Pharmaceuticals
Chase Pharmaceuticals

Pioneering advancements in neuropsychiatric treatment for a brighter future

Series B
11-50 employees
Biotechnology, Health Care
Newron Pharmaceuticals SpA vs
PsychoGenics
PsychoGenics United States

Discover Your Next Breakthrough

Grant
146 employees
Biotechnology, Health Care
Newron Pharmaceuticals SpA vs
Acadia Pharmaceuticals
Acadia Pharmaceuticals United States

Acadia is trailblazing breakthroughs in neuroscience to elevate life.

Post-IPO Equity
1028 employees
Biotechnology, Health Care
Also compare with: Newron Pharmaceuticals SpA vs Karuna Therapeutics Karuna Therapeutics Newron Pharmaceuticals SpA vs Lyndra Therapeutics Lyndra Therapeutics View all alternatives

FAQ About Newron Pharmaceuticals SpA

The Specialist in CNS Drug Development
Newron Pharmaceuticals SpA was founded in 1999.
Newron Pharmaceuticals SpA is headquartered in Italy.
Newron Pharmaceuticals SpA operates in Biopharma, Biotechnology and Health Care. Its work centres on biopharmaceutical, CNS drug development, Parkinson's disease treatment and neurological disorders.
Newron Pharmaceuticals SpA has approximately 23 employees.
Newron Pharmaceuticals SpA has completed 10 funding rounds, raising a total of $129.36M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Newron Pharmaceuticals SpA include Chase Pharmaceuticals, PsychoGenics, Acadia Pharmaceuticals, Addex Therapeutics, Asceneuron SA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Newron Pharmaceuticals SpA and Chase Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Newron Pharmaceuticals SpA, https://bouncewatch.com/company/newron-pharmaceuticals, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout